Market Cap
€262.0m
Last Updated
2020/07/11 21:01 UTC
Data Sources
Company Financials +
Executive Summary
Formycon AG develops and markets biosimilar products.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Adequate balance sheet with concerning outlook.
Share Price & News
How has Formycon's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: FYB's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
13.9%
FYB
-0.2%
DE Biotechs
0.7%
DE Market
1 Year Return
-12.4%
FYB
8.6%
DE Biotechs
3.9%
DE Market
Return vs Industry: FYB underperformed the German Biotechs industry which returned 8.6% over the past year.
Return vs Market: FYB underperformed the German Market which returned 3.9% over the past year.
Shareholder returns
| FYB | Industry | Market | |
|---|---|---|---|
| 7 Day | 13.9% | -0.2% | 0.7% |
| 30 Day | 11.5% | 5.5% | 1.4% |
| 90 Day | 24.8% | 18.0% | 17.3% |
| 1 Year | -12.4%-12.4% | 8.8%8.6% | 6.2%3.9% |
| 3 Year | -22.3%-22.3% | 15.5%14.8% | 1.8%-6.2% |
| 5 Year | -4.7%-4.7% | 9.9%8.8% | 9.3%-5.4% |
Price Volatility Vs. Market
How volatile is Formycon's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Did Changing Sentiment Drive Formycon's (ETR:FYB) Share Price Down By 38%?8 months ago | Simply Wall St
Does Formycon AG (ETR:FYB) Have A Volatile Share Price?9 months ago | Simply Wall St
Announcing: Formycon (ETR:FYB) Stock Increased An Energizing 268% In The Last Five YearsValuation
Is Formycon undervalued compared to its fair value and its price relative to the market?
5.43x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate FYB's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate FYB's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: FYB is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.
PE vs Market: FYB is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate FYB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: FYB is overvalued based on its PB Ratio (5.4x) compared to the DE Biotechs industry average (2.8x).
Next Steps
Future Growth
How is Formycon forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
10.3%
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if FYB's forecast earnings growth is above the savings rate (0.2%).
Earnings vs Market: Insufficient data to determine if FYB's earnings are forecast to grow faster than the German market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: FYB's revenue (10.3% per year) is forecast to grow faster than the German market (5.9% per year).
High Growth Revenue: FYB's revenue (10.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if FYB's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Formycon performed over the past 5 years?
19.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FYB is currently unprofitable.
Growing Profit Margin: FYB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: FYB is unprofitable, but has reduced losses over the past 5 years at a rate of 19.3% per year.
Accelerating Growth: Unable to compare FYB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FYB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.5%).
Return on Equity
High ROE: FYB has a negative Return on Equity (-4.76%), as it is currently unprofitable.
Next Steps
Financial Health
How is Formycon's financial position?
Financial Position Analysis
Short Term Liabilities: FYB's short term assets (€28.1M) exceed its short term liabilities (€4.6M).
Long Term Liabilities: FYB's short term assets (€28.1M) exceed its long term liabilities (€726.7K).
Debt to Equity History and Analysis
Debt Level: FYB is debt free.
Reducing Debt: FYB had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if FYB has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if FYB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Formycon current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate FYB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FYB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if FYB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FYB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of FYB's dividend in 3 years as they are not forecast to pay a notable one for the German market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
5.4yrs
Average board tenure
CEO
Carsten Brockmeyer
7.25yrs
Tenure
Dr. Carsten Brockmeyer, PhD, has been Chief Executive Officer and Member of Executive Board at Formycon AG since April 16, 2013 and served as its Chairman of Executive Board. Dr. Brockmeyer has more than 2 ...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Member of Advisory Board | 6.33yrs | no data | no data | |
| Member of Advisory Board | 6.67yrs | no data | no data | |
| Deputy Chairman of Supervisory Board | no data | no data | no data | |
| Chairman of Supervisory Board | no data | no data | no data | |
| Member of Supervisory Board | no data | no data | no data | |
| Member of Advisory Board | 4.42yrs | no data | no data | |
| Member of Advisory Board | 1.92yrs | no data | no data |
5.4yrs
Average Tenure
Experienced Board: FYB's board of directors are considered experienced (5.4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.1%.
Top Shareholders
Company Information
Formycon AG's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Formycon AG
- Ticker: FYB
- Exchange: XTRA
- Founded: 1999
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €262.000m
- Shares outstanding: 10.00m
- Website: https://www.formycon.com
Number of Employees
Location
- Formycon AG
- Fraunhoferstrasse 15
- Martinsried
- Planegg
- Bavaria
- 82152
- Germany
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| FYB | DB (Deutsche Boerse AG) | Yes | Bearer Shares | DE | EUR | Dec 2010 |
| FYB | XTRA (XETRA Trading Platform) | Yes | Bearer Shares | DE | EUR | Dec 2010 |
| 0W4N | LSE (London Stock Exchange) | Yes | Bearer Shares | GB | EUR | Dec 2010 |
| FYBD | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Bearer Shares | GB | EUR | Dec 2010 |
Biography
Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis 1, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases that has completed Phase III clinical trials; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase I clinical trial; and FYB203, a biosimilar candidate for Eylea 3, like Lucentis, Eylea, used to treat neovascular age-related macular degeneration and other eye diseases. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/07/11 21:01 |
| End of Day Share Price | 2020/07/10 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.